- 09/15/2016
- eisai receives license for new indication for anticancer agent kisplyx® ▼ (lenvatinib mesylate) for treatment of advanced renal cell carcinoma
- 09/14/2016
- eisai selected for fourth consecutive year of membership in dow jones sustainability asia pacific index 2016
- 09/04/2016
- “not only for classics” -- a record on eisai china 2016 peripheral neuropathy forum
- 08/23/2016
- eisai to launch chocola bb® mouth ulcer repair shot -- first mouth ulcer spray for the chocola bb brand
- 08/09/2016
- u.s. fda confirms sufficient data to advance investigational bace inhibitor e2609 for treatment of early alzheimer’s disease to phase iii planning underway towards phase iii study initiation in fy2016
- 07/22/2016
- eisai receives positive chmp opinion on new indication for anticancer agent lenvatinib in combination with everolimus for treatment of advanced renal cell carcinoma
- 07/19/2016
- u.s. fda approves belviq xr®, a once-daily formulation of lorcaserin for chronic weight management
- 07/15/2016
- antiobesity agent venespri® (lorcaserin) approved in mexico - first country in latin america to approve lorcaserin
- 07/11/2016
- eisai china, trip to guizhou - record on guizhou green expo, big health & pharmaceutical industry fair and summit
- 06/27/2016
- eisai china participated in the 2nd annual scientific session of chinese stroke association (csa) and tiantan international stroke conference (tisc) -- focus on post-stroke cognitive impairment (psci)
